The ongoing pandemic of coronavirus disease (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an emerging, rapidly evolving situation. As of March 30, 2020, a total of 735,560 confirmed cases and 34,830 deaths had been reported in at least 174 countries, indicating that the overall rate of death from COVID-19 pneumonia was 4.7% ([@bib1]). In the first cohort of 41 patients with COVID-19 pneumonia from Wuhan, China, 13 patients (31.7%) were admitted to an intensive care unit (ICU) and 6 (14.6%) died ([@bib2]). When the cohort size expanded to 99 cases, 11 patients (11.1%) worsened in a short period of time and died of multiple organ failure ([@bib3]). Recent studies have demonstrated that older age, higher Sequential Organ Failure Assessment (SOFA) scores, and elevated D-dimer are risk factors for death in patients with COVID-19 pneumonia ([@bib4]--[@bib6]), and that high fever (≥39°C) is associated with a lower likelihood of death ([@bib6]). However, these studies have not reported the issues faced around the world with regard to the rapid increase in cases potentially overwhelming healthcare resources. Between December 25, 2019, and February 15, 2020, a total of 1,017 patients with confirmed COVID-19 pneumonia were admitted to one special hospital for infectious diseases and two general hospitals in Wuhan. As of February 24, 2020, 114 patients had died in the hospitals, and data required for this study were available for 109 of these patients. This report describes the clinical course and critical care of these 109 decedents from the initial Wuhan experience to address the issues concerning ICU resources.

Methods
=======

Patients
--------

In response to a pandemic of COVID-19 pneumonia, all hospitals in Wuhan initiated active surveillance for the disease on December 31, 2019 at the requirement of the Wuhan Health Commission. Between December 25, 2019, and February 15, 2020, the numbers of patients with COVID-19 pneumonia who had been admitted to Wuhan Pulmonary Hospital (Pulmonary Hospital), Tianyou Hospital Affiliated with the Wuhan University of Science and Technology (Tianyou Hospital), and Central Hospital of Wuhan (Central Hospital) were 273, 301, and 443, respectively. A diagnosis of COVID-19 pneumonia was confirmed according to the case definition established by World Health Organization interim guidance with positive SARS-CoV-2 test results in throat-swab specimens ([@bib7]).

Data Collection
---------------

We retrospectively collected the demographics, clinical symptoms or signs, laboratory findings on admission and during hospitalization, treatment, and date of death from electronic medical records of the decedents. Data were entered into a computerized database and cross-checked. Ethics approval was exempted by the institutional review boards of the hospitals because we collected and analyzed all data from the patients according to the policy for public health outbreak investigations of emerging infectious diseases issued by the National Health Commission of the People's Republic of China. Two researchers independently reviewed the data collection forms to double-check the collected data.

Statistical Analysis
--------------------

Descriptive data are presented as frequencies (percentages) for discrete variables and as means (standard deviations \[SDs\]) or medians (interquartile ranges \[IQRs\]) for continuous variables. Comparisons were performed using Student's *t* test or Mann-Whitney *U* test for continuous variables as appropriate, and the χ^2^ test for categorical variables. The statistical significance level was set at 0.05 (two-tailed). All analyses were conducted with MedCalc and SPSS version 23.0 statistical software.

Results
=======

Characteristics of the Study Patients
-------------------------------------

In Wuhan city, a total of 48 hospitals (35 in urban districts and 13 in suburban areas) were designated as "COVID-19 hospitals" by the local government. Pulmonary Hospital and Jinyintan Hospital are the two special hospitals for infectious diseases in Wuhan. It was local policy to transfer critically ill patients with COVID pneumonia from general hospitals, including Tianyou Hospital and Central Hospital, to the special hospitals for treatment. During the study period, 1,017 patients with confirmed COVID-19 pneumonia were admitted to our three study hospitals. As of February 24, 2020, the numbers (percentages) of dead patients in Pulmonary Hospital, Tianyou Hospital, and Central Hospital were 45 (16.5%), 29 (9.6%), and 40 (9.0%), respectively. In Central Hospital, 40 nonsurvivors were distributed among different wards. Five of these patients died within a few hours after they were admitted to the hospital and thus the required data could not be obtained; therefore, only 35 cases were included in the present study. In total, the study population of this multicenter observational study consisted of 109 decedents.

Throat-swab specimens from the 109 decedents showed positive SARS-CoV-2 test results. Pulmonary involvement was seen on computed tomography of all of the patients, and the most frequent computed tomography findings were bilateral extensive ground-glass opacification and/or consolidation.

The mean age of the patients with COVID-19 pneumonia was 70.7 years (SD = 10.9 yr; range 43--99 yr), and 35 patients (32.1%) were female ([Table 1](#tbl1){ref-type="table"}). Three patients (2.8%) were \<50 years old, and 76.1% were ≥65 years old. Eight-five patients (78.0%) suffered from one or more underlying comorbidities, with the three most common being hypertension, cardiovascular or cerebrovascular disease, and diabetes ([Table 1](#tbl1){ref-type="table"}).

###### 

Demographics and clinical presentation of 109 decedents with COVID-19 pneumonia

  Characteristic                                 Total (*N* = *109*)   ICU (*n* = *51*)    Non-ICU (*n* = *58*)   *P* Value
  --------------------------------------------- --------------------- ------------------- ---------------------- -----------
  Age, yr                                                                                                              
   Mean ± SD, yr                                     70.7 ± 10.9          68.4 ± 9.7           72.7 ± 11.6          0.038
   Subgroup, *n* (%)                                     ---                  ---                  ---              0.005
    ≤49 yr                                             3 (2.8)              3 (5.9)               0 (0)              ---
    50--64 yr                                         23 (21.1)            10 (19.6)            13 (22.4)            ---
    65--74 yr                                         45 (41.3)            27 (52.9)            18 (31.0)            ---
    ≥75 yr                                            38 (34.8)            11 (21.6)            27 (46.6)            ---
  Female, *n* (%)                                     35 (32.1)            15 (29.4)            20 (34.5)           0.572
  Underlying diseases, *n* (%)                                                                                         
   Hypertension                                       65 (59.6)            29 (56.9)            36 (62.1)           0.580
   Cardiovascular or cerebrovascular diseases         37 (33.9)            15 (29.4)            22 (37.9)           0.349
   Diabetes                                           34 (31.2)            18 (35.3)            16 (27.6)           0.386
   Chronic respiratory disease                        17 (15.6)             4 (7.8)             13 (22.4)           0.036
   Chronic digestive disorders                        16 (14.7)            6 (11.8)             10 (17.2)           0.420
   Chronic renal insufficiency                         8 (7.3)              1 (2.0)              7 (12.1)           0.099
   Peripheral vascular disease                         8 (7.3)              2 (3.9)              6 (10.3)           0.360
   Malignancy                                          8 (7.3)              2 (3.9)              6 (10.3)           0.360
   Chronic hepatic insufficiency                       2 (1.8)               0 (0)               2 (3.4)            0.497
   Autoimmune diseases                                 1 (0.9)              1 (2.0)               0 (0)             0.468
  Symptoms at onset of illness, *n* (%)                                                                                
   Fever                                              99 (90.8)            49 (96.1)            50 (86.2)           0.147
   Cough                                              77 (70.6)            36 (70.6)            41 (70.7)           0.991
   Dyspnea                                            75 (68.8)            38 (74.5)            37 (63.8)           0.228
   Fatigue                                            58 (53.2)            22 (43.1)            36 (62.1)           0.048
   Sputum production                                  47 (43.1)            21 (41.2)            26 (44.8)           0.701
   Diarrhea                                           29 (26.6)            15 (29.4)            14 (24.1)           0.534
   Myalgia                                            19 (17.4)            12 (23.5)             7 (12.1)           0.116
   Headache                                            8 (7.3)              4 (7.8)              4 (6.9)            1.000
   Hemoptysis                                          8 (7.3)             6 (11.8)              2 (3.4)            0.196
  Vital signs on admission                                                                                             
   Temperature                                                                                                         
    Median (IQR), °C                              36.6 (36.4--37.2)    36.6 (36.5--37.3)    36.6 (36.4--37.2)       0.367
    Subgroup, *n* (%)                                    ---                  ---                  ---              0.184
     \<37.3°C                                         83 (76.1)            38 (74.5)            45 (77.6)            ---
     37.3--38.0°C                                     17 (15.6)            7 (13.7)             10 (17.2)            ---
     38. 1--39.0°C                                     6 (5.5)              3 (5.9)              3 (5.2)             ---
     \>39.0°C                                          3 (2.8)              3 (5.9)               0 (0)              ---
   Systolic blood pressure, mm Hg                     132 ± 22             131 ± 23              133 ± 22           0.713
   Diastolic blood pressure, mm Hg                     75 ± 12              73 ± 11              76 ± 13            0.326
   Respiratory rate                                                                                                    
    Median (IQR), breath/min                         20 (20--26)          21 (20--28)          20 (20--25)          0.387
    \>24 breaths/min, *n* (%)                         32 (29.4)            17 (33.3)            15 (25.9)           0.393
   Heart rate                                                                                                          
    Mean ± SD, breath/min                            88.5 ± 18.5          92.3 ± 19.6          85.2 ± 16.9          0.043
    \>100 beats/min, *n* (%)                          29 (26.6)            17 (33.3)            12 (20.7)           0.136
  APACHE II score                                 22.0 (16.0--34.8)    26.5 (17.0--35.3)    21.0 (14.8--33.5)       0.163
  SOFA score                                       3.0 (2.0--6.0)       3.0 (2.0--7.0)        3.0 (2.0--6.0)        0.880

*Definition of abbreviations*: APACHE II = Acute Physiology and Chronic Health Evaluation II; COVID-19 = coronavirus disease; ICU = intensive care unit; IQR = interquartile range; SD = standard deviation; SOFA = Sequential Organ Failure Assessment.

Comparisons were determined by Student's *t* test, Mann-Whitney *U* test, or χ^2^ test as appropriate.

At the onset of illness, fever, fatigue, and dry cough were the three most common symptoms reported in the overall population ([@bib2], [@bib8]). We noted that dyspnea took the place of fatigue, becoming one of the top three symptoms of decedents, followed by fatigue, sputum production, and diarrhea ([Table 1](#tbl1){ref-type="table"}). On admission to the hospital, all of the patients were critically ill, and the most frequent and most significant symptom was rapid, progressive dyspnea. As shown in [Table 1](#tbl1){ref-type="table"}, the medians of Acute Physiology and Chronic Health Evaluation (APACHE) II scores and SOFA scores were 22.0 and 3.0, respectively, indicating that more severe conditions, including multiple organ injury, were common.

The numbers of ICU beds provided for patients with COVID-19 were 21, 10, and 12 in Pulmonary Hospital, Tianyou Hospital, and Central Hospital, respectively. All 109 hospitalized patients needed ICU admission; however, because of very limited availability, only 51 (46.8%) could be admitted. As a matter of fact, during this study period, only after someone in the ICU had died could the next patient be admitted to occupy the ICU bed. When we compared the demographic and clinical characteristics of patients who were admitted to the ICU with those of the patients who were not, we noted that most characteristics, including APACHE II and SOFA scores, were similar, except that younger age, less underlying chronic respiratory disease, less fatigue symptoms, and faster heart rates were seen in the ICU group ([Table 1](#tbl1){ref-type="table"}).

Laboratory Findings
-------------------

The white blood cell numbers in 55.0% of the decedents with COVID pneumonia were not outside the normal range: 31.2% were above the upper boundary of normal range, and approximately half had increased neutrophilic granulocytosis ([Table 2](#tbl2){ref-type="table"}). Lymphopenia is always a leading feature of viral pneumonia. Similar to findings from the overall population of patients with COVID-19 pneumonia throughout China ([@bib9]), a majority (82.6%) of decedents in our study demonstrated a remarkable lymphopenia; only one (0.9%) had lymphocyte numbers above the upper boundary of normal range. In addition, anemia and thrombocytopenia were also common ([Table 2](#tbl2){ref-type="table"}). As shown in Figure E1 in the online supplement, leukocytosis, neutrophilic granulocytosis, lymphopenia, and anemia occurred right after hospitalization and lasted for at least 2 weeks or until death.

###### 

Blood analysis in 109 decedents with COVID-19 pneumonia

  Parameter                                                              Total (*N* = *109*)        ICU (*n* = *51*)       Non-ICU (*n* = *58*)    *P* Value
  -------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ -----------
  White blood cells                                                                                                                                     
   Mean ± SD, ×10^9^/L                                                        8.7 ± 4.8                9.6 ± 5.5                7.9 ± 4.1            0.067
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.897
    \<4 × 10^9^/L                                                             15 (13.8)                 7 (13.7)                 8 (13.8)             ---
    4--10 × 10^9^/L                                                           60 (55.0)                27 (52.9)                33 (56.9)             ---
    \>10 × 10^9^/L                                                            34 (31.2)                17 (33.3)                17 (29.3)             ---
  Neutrophils                                                                                                                                           
   Mean ± SD,×10^9^/L                                                         7.5 ± 4.6                8.3 ± 5.2                6.9 ± 4.1            0.101
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.033
    \<1.8 × 10^9^/L                                                            4 (3.7)                   0 (0)                   4 (6.9)              ---
    1.8--6.3 × 10^9^/L                                                        50 (45.9)                21 (41.2)                29 (50.0)             ---
    \>6.3 × 10^9^/L                                                           55 (50.5)                30 (58.8)                25 (43.1)             ---
  Lymphocytes                                                                                                                                           
   Median (IQR), ×10^9^/L                                                   0.6 (0.4--0.9)           0.6 (0.4--0.9)           0.6 (0.5--0.8)         0.817
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.696
    \<1.1 × 10^9^/L                                                           90 (82.6)                41 (80.4)                49 (84.5)             ---
    1.1--3.2 × 10^9^/L                                                        18 (16.5)                 9 (17.6)                 9 (15.5)             ---
    \>3.2 × 10^9^/L                                                            1 (0.9)                  1 (2.0)                   0 (0)               ---
  Red blood cells                                                                                                                                       
   Mean ± SD, ×10^12^/L                                                       4.2 ± 0.7                4.3 ± 0.6                4.0 ± 0.8            0.022
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.051
    \<4.3 × 10^12^/L                                                          62 (56.9)                24 (47.1)                38 (65.5)             ---
    4.3--5.8 × 10^12^/L                                                       46 (42.2)                27 (52.9)                19 (32.8)             ---
    \>5.8 × 10^12^/L                                                           1 (0.9)                   0 (0)                   1 (1.7)              ---
  Hemoglobulin                                                                                                                                          
   Mean ± SD, g/L                                                            125.8 ± 21.2             131.2 ± 17.3             121.0 ± 23.2          0.010
   \<110 g/L, *n* (%)                                                         19 (17.4)                 4 (7.8)                 15 (25.9)            0.013
  Platelets                                                                                                                                             
   Mean ± SD, × 10^9^/L                                                      169.4 ± 78.4             169.2 ± 72.5             169.5 ± 83.9          0.983
   \<100 × 10^9^/L, *n* (%)                                                   16 (14.7)                 7 (13.7)                 9 (15.5)            0.792
  C-reactive protein                                                                                                                                    
   Mean ± SD, mg/L                                                           85.7 ± 57.3              87.1 ± 63.0              84.5 ± 52.3           0.815
   ≥10 mg/L, *n* (%)                                                          104 (95.4)               48 (94.1)                56 (96.6)            0.883
  Procalcitonin                                                                                                                                         
   Median (IQR), μg/L                                                       0.1 (0.1--0.3)           0.1 (0.1--0.4)           0.1 (0.0--0.3)         0.395
   ≥0.5 μg/L, *n* (%)                                                         20 (18.3)                10 (19.6)                10 (17.2)            0.750
  Pa~O~2~~                                                                                                                                              
   Mean ± SD, mm Hg                                                          62.3 ± 25.4              63.6 ± 27.4              61.1 ± 23.6           0.617
   \<80 mm Hg, *n* (%)                                                        91 (83.5)                42 (82.4)                49 (84.5)            0.765
  Sa~O~2~~                                                                                                                                              
   Median (IQR),%                                                         90.0 (80.5--94.0)        90.0 (80.0--95.0)        90.0 (81.5--93.3)        0.803
   \<95%, *n* (%)                                                             84 (77.1)                38 (74.5)                46 (79.3)            0.552
  Pa~O~2~~/F[i]{.smallcaps}~O~2~~                                                                                                                       
   Median (IQR), mm Hg                                                      124 (90--186)            121 (90--158)            133 (90--230)          0.143
   \<200 mm Hg, *n* (%)                                                       84 (77.1)                43 (84.3)                41 (70.7)            0.091
  Cardiac troponin I                                                                                                                                    
   Median (IQR), μg/L                                                       0.0 (0.0--0.1)           0.0 (0.0--0.1)           0.0 (0.0--0.1)         0.543
   ≥0.05 μg/L, *n* (%)                                                        52 (47.7)                25 (49.0)                27 (46.6)            0.797
  Creatine kinase MB                                                                                                                                    
   Median (IQR), μg/L                                                       3.0 (1.7--9.5)           2.7 (1.4--7.0)          3.9 (1.7--10.7)         0.182
   \>5 μg/L, *n* (%)                                                          39 (35.8)                15 (29.4)                24 (41.4)            0.193
  Myoglobin                                                                                                                                             
   Median (IQR), μg/L                                                     68.3 (36.6--141.1)       71.4 (37.3--153.9)       68.1 (35.5--133.7)       0.491
   \>100 μg/L, *n* (%)                                                        42 (38.5)                23 (45.1)                19 (32.8)            0.187
  NT-pro-brain natriuretic peptide[\*](#tblfn1){ref-type="table-fn"}                                                                                    
   Median (IQR), ng/L                                                   582.0 (307.0--1,097.5)   480.0 (164.0--1,046.5)   722.0 (498.5--1,335.0)     0.134
   \>300 ng/L, *n* (%)                                                       34/45 (75.6)             18/28 (64.3)             16/17 (94.1)          0.057
  Albumin                                                                                                                                               
   Median (IQR), g/L                                                      34.2 (31.6--37.0)        33.2 (30.7--35.2)        35.6 (32.0--38.9)        0.011
   \<40 g/L, *n* (%)                                                          92 (84.4)                47 (92.2)                45 (77.6)            0.036
  Alanine aminotransferase                                                                                                                              
   Median (IQR), U/L                                                      24.0 (19.0--39.0)        27.0 (21.0--45.0)        21.6 (16.8--36.5)        0.103
   \>50 U/L, *n* (%)                                                          18 (16.5)                10 (19.6)                 8 (13.8)            0.415
  Aspartate aminotransferase                                                                                                                            
   Median (IQR), U/L                                                      37.0 (25.7--50.0)        40.0 (27.0--56.0)        32.0 (24.8--47.0)        0.216
   \>40 U/L, *n* (%)                                                          50 (45.9)                25 (49.0)                25 (43.1)            0.536
  Urea nitrogen                                                                                                                                         
   Median (IQR), mmol/L                                                    7.3 (5.7--10.1)           7.3 (5.4--8.7)          7.7 (5.7--12.4)         0.101
   \>8 mmol/L, *n* (%)                                                        43 (39.4)                16 (31.4)                27 (46.6)            0.106
  Creatinine                                                                                                                                            
   Median (IQR), μmol/L                                                   76.0 (62.3--96.0)        71.0 (58.0--86.0)        85.8 (70.0--110.3)       0.002
   \>133 μmol/L, *n* (%)                                                      12 (11.0)                 2 (3.9)                 10 (17.2)            0.027
  D-dimer, mg/L                                                                                                                                         
   Median (IQR), mg/L                                                       1.4 (0.6--4.8)           2.3 (0.9--7.5)           1.0 (0.4--4.2)         0.011
   \>0.5 mg/L, *n* (%)                                                        85 (78.0)                44 (86.3)                41 (70.7)            0.050
  Prothrombin time                                                                                                                                      
   Median (IQR), s                                                        12.9 (11.6--15.4)        13.6 (12.1--16.0)        12.3 (11.3--14.4)        0.007
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.023
    \<11.0 s                                                                  13 (11.9)                 3 (5.9)                 10 (17.2)             ---
    11.0--13.0 s                                                              44 (40.4)                17 (33.3)                27 (46.6)             ---
    \>13.0 s                                                                  52 (47.7)                31 (60.8)                21 (36.2)             ---
  Activated partial thromboplastin time                                                                                                                 
   Median (IQR), s                                                           34.3 ± 10.7              35.0 ± 11.9               33.8 ± 9.6           0.546
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.545
    \<21.0 s                                                                   7 (6.4)                  2 (3.9)                  5 (8.6)              ---
    21.0--34.0 s                                                              54 (49.5)                27 (52.9)                27 (46.6)             ---
    \>34.0 s                                                                  48 (44.1)                22 (43.2)                26 (44.8)             ---
  Potassium                                                                                                                                             
   Mean ± SD, mmol/L                                                          4.1 ± 0.6                4.0 ± 0.7                4.1 ± 0.6            0.650
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.700
    \<3.5 mmol/L                                                              16 (14.7)                 9 (17.7)                 7 (12.1)             ---
    3.5--5.5 mmol/L                                                           89 (81.7)                40 (78.4)                49 (84.5)             ---
    \>5.5 mmol/L                                                               4 (3.7)                  2 (3.9)                  2 (3.4)              ---
  Sodium                                                                                                                                                
   Mean ± SD, mmol/L                                                         138.8 ± 5.3              139.2 ± 4.8              138.5 ± 5.7           0.508
   Subgroup, *n* (%)                                                             ---                      ---                      ---               0.753
    \<135 mmol/L                                                              24 (22.0)                10 (19.6)                14 (24.1)             ---
    135--145 mmol/L                                                           73 (67.0)                36 (70.6)                37 (63.8)             ---
    \>145 mmol/L                                                              12 (11.0)                 5 (9.8)                  7 (12.1)             ---

*Definition of abbreviations*: COVID-19 = coronavirus disease; F[i]{.smallcaps}~O~2~~ = fraction of inspired oxygen; ICU = intensive care unit; IQR = interquartile range; Pa~O~2~~ = arterial partial pressure of oxygen; Sa~O~2~~ = arterial oxygen saturation; SD = standard deviation.

Comparisons were determined by Student's *t* test, Mann-Whitney *U* test, or χ^2^ test as appropriate.

Data from 45 patients in Wuhan Pulmonary Hospital.

All of the patients were severely hypoxemic, as indicated by a remarkable decrease in arterial oxygen pressure, arterial oxygen saturation, and the ratio of arterial oxygen pressure/fraction of inspired oxygen at hospital admission ([Table 2](#tbl2){ref-type="table"} and Figure E2). They suffered more frequent and more severe heart injuries, as an elevation in all laboratory parameters reflecting heart injury, including cardiac troponin I, creatine kinase MB, myoglobin, and NT-pro-brain natriuretic peptide, was seen in a high proportion of the decedents ([Table 2](#tbl2){ref-type="table"}). Furthermore, they exhibited such high concentrations above the upper boundaries of normal ranges for at least the first 2 weeks (Figure E3). In some patients, the concentrations of alanine aminotransferase, aspartate aminotransferase, urea nitrogen, and creatinine were increased, especially in the late stage of illness ([Table 2](#tbl2){ref-type="table"} and Figure E4), indicating that they were also susceptible to hepatic or renal insufficiency. Multiple organ failure was further manifested by coagulation disorders, as D-dimer concentrations were elevated, and prothrombin time and activated partial thromboplastin time were prolonged, and these abnormalities were long lasting ([Table 2](#tbl2){ref-type="table"} and Figure E5).

A comparison of laboratory findings from the ICU group and non-ICU group demonstrated some statistical differences in anemia, hypoproteinemia, creatinine, D-dimer, and prothrombin time ([Table 2](#tbl2){ref-type="table"}); however, these differences did not show any clinical significance.

Treatment
---------

The mean duration that patients with COVID-19 pneumonia had to wait for a hospital bed was 9.7 days (SD = 5.3 d). One day (range, 0--4 d) after hospitalization, 51 patients had an opportunity to be transferred from a non-ICU setting to an ICU. After they were admitted to the ICU, these patients stayed there for 11.8 days (SD = 8.8 d) before they died. Overall, the mean time from onset of symptoms to death was 22.3 days (SD = 9.2 d) ([Table 3](#tbl3){ref-type="table"}). As shown in [Figure 1](#fig1){ref-type="fig"}, 66.1% of the patients (72/109) died in the first 15 days after hospitalization, and 70.6% (36/51) died in the first 15 days after ICU admission. As expected, patients in the ICU group lived longer than those in the non-ICU group ([Table 3](#tbl3){ref-type="table"}). Given that the surge in patients requiring ICU admission was overwhelming, and that there were no specific decision rules, risk scores, or criteria for deciding who should receive ICU admission in China, our physicians made the decision at their sole discretion.

###### 

Treatments in 109 decedents with COVID-19 pneumonia

  Treatment                                             Total (*N* = *109*)   ICU (*n* = *51*)   Non-ICU (*n* = *58*)   *P* Value
  ---------------------------------------------------- --------------------- ------------------ ---------------------- -----------
  Onset of symptom to, mean ± SD, d                                                                                          
   Hospitalization[\*](#tblfn2){ref-type="table-fn"}         9.7 ± 5.3           10.5 ± 4.9           9.0 ± 5.5           0.128
   ICU admission                                            14.0 ± 7.6           14.0 ± 7.6              ---               ---
   Death                                                    22.3 ± 9.2           24.8 ± 9.4           20.1 ± 8.5          0.007
  Period of hospitalization, mean ± SD, d                   14.1 ± 8.8           15.9 ± 8.8           12.5 ± 8.6          0.044
  ICU admission                                                                                                              
   *n* (%)                                                   51 (46.8)            51 (100)               ---               ---
   Period, d                                                11.8 ± 8.8           11.8 ± 8.8              ---               ---
  Period of hospitalization to ICU, d                      1.0 (0--4.0)         1.0 (0--4.0)             ---               ---
  Antibiotics, *n* (%)                                       109 (100)            51 (100)             58 (100)            ---
  Antiviral drugs, *n* (%)                                  103 (94.5)           49 (96.1)            54 (93.1)           0.796
  Antifungal drugs, *n* (%)                                  20 (18.3)           20 (39.2)              0 (0)            \<0.001
  Glucocorticoids, *n* (%)                                   83 (76.1)           34 (66.7)            49 (84.5)           0.029
  Intravenous immune globulin, *n* (%)                       66 (60.6)           41 (80.4)            25 (43.1)          \<0.001
  Anticoagulant therapy, *n* (%)                             42 (38.5)           26 (51.0)            16 (27.6)           0.012
  Oxygen therapy                                                                                                             
   High-flow nasal cannula oxygen therapy, *n* (%)           43 (39.4)           21 (41.2)            22 (37.9)           0.729
   Mechanical ventilation, *n* (%)                                                                                           
    Noninvasive                                              64 (58.7)           39 (76.5)            25 (43.1)          \<0.001
    Invasive                                                 33 (30.3)           33 (64.7)              0 (0)            \<0.001
  Continuous renal-replacement therapy, *n* (%)              12 (11.0)           10 (19.6)             2 (3.4)            0.007
  Extracorporeal membrane oxygenation, *n* (%)                7 (6.4)             7 (13.7)              0 (0)             0.012

*Definition of abbreviations*: COVID-19 = coronavirus disease; ICU = intensive care unit; SD = standard deviation.

Comparisons were determined by Student's *t* test or χ^2^ test as appropriate.

Data were obtained from 107 patients, as 2 patients were hospitalized because of other diseases; *n* = 50 in the ICU group and *n* = 57 in the non-ICU group.

![(*A* and *B*) Distribution of time to death after hospitalization (*A*, *N* = 109) and after admission to an intensive care unit (*B*, *n* = 51) among decedents with coronavirus disease (COVID-19) pneumonia.](AnnalsATS.202003-225OC_f1){#fig1}

As shown in [Table 3](#tbl3){ref-type="table"}, all patients (100%) were administered antibiotics to prevent or treat coexisting or secondary bacterial infection, and almost all patients in the ICU group (96.1%) and non-ICU group (93.1%) were administered antiviral drugs (oseltamivir or peramivir) to treat possible influenza. Twenty of the patients (39.2%) in the ICU group, but none in the non-ICU group, were given antifungal drugs. However, actual lung bacterial or fungal infections were documented in only 42 patients (38.5%).

In the hope of alleviating a severe inflammatory response, glucocorticoids were given to 83 patients (76.1%), and to enhance immunocompetence, intravenous immune globulin was given to 66 patients (60.6%) ([Table 3](#tbl3){ref-type="table"}). As indicated by an elevation of D-dimer and extension of prothrombin time and/or activated partial thromboplastin time, anticoagulant therapy was given to 42 patients (38.5%). In addition, immune globulin and anticoagulant therapy was given to more patients in the ICU group than in the non-ICU group ([Table 3](#tbl3){ref-type="table"}).

In response to rapidly progressive hypoxemia, oxygen therapy was provided for all patients, including high-flow nasal cannula oxygen therapy (39.4%), noninvasive mechanical ventilation (58.7%), and invasive ventilation (30.3%). In addition, 12 patients (11.0%) received continuous renal-replacement therapy, and 7 (6.4%) received extracorporeal membrane oxygenation ([Table 3](#tbl3){ref-type="table"}). In our settings, invasive ventilation and extracorporeal membrane oxygenation could only be performed in the ICU. All 51 patients who were admitted to the ICU needed invasive mechanical ventilation; unfortunately, owing to a lack of ventilators, only 33 (64.7%) received it.

Discussion
==========

This multicenter observational study of 109 decedents indicated that mortality due to COVID-19 pneumonia was concentrated in people above the age of 65 years, especially those with major comorbidities, and that 51 patients who were admitted to an ICU lived longer than 58 patients who were not. Healthcare systems must address the difficult issue of allocating ICU resources when facing overwhelming numbers of critically ill patients. Our three designated COVID-19 hospitals had a total of 1,379 beds; however, only 43 ICU beds were available for patients with severe COVID-19 pneumonia. All 51 patients who were admitted to the ICU died there; because of the rapidly progressive nature of this disease, none had a chance to be transferred to a general ward. Given that the number of critically ill patients with COVID-19 pneumonia far exceeded the number of ICU beds, and that no specific decision rules, risk scores, or criteria were available to determine who should receive ICU admission, our physicians made the decision at their sole discretion. Usually, during the study period, only after someone in an ICU died could the next patient be transferred into that ICU. Occasionally (if at all), the physicians tended to allocate ICU care to the younger patients, as they seemed to have a greater chance of surviving.

It is not surprising that there were approximately twice as many men as women among the nonsurvivors with COVID-19 pneumonia, as in most infectious diseases and related conditions, such as sepsis and septic shock, men always account for a larger proportion of cases and have a higher mortality ([@bib10], [@bib11]). In a single-center retrospective study, 32 nonsurvivors were of older age and more likely to have a preexisting chronic medical illness ([@bib12]). In the present study, we noted that only 3 (2.8%) of the decedents were younger than 50 years, and 83 (76.1%) were above the age of 65 years. We also noted that most patients suffered from underlying comorbidities, with the most common ones being hypertension, cardiovascular or cerebrovascular diseases, diabetes, and chronic digestive disorders. In contrast, severe disease and mortality from 2009 influenza A (H1N1) infection is concentrated in relatively healthy adolescents and adults between the ages of 10 and 60 years without major comorbidities ([@bib13]--[@bib15]).

A pathological study of a patient who died from COVID-19 pneumonia revealed bilateral diffuse alveolar damage with cellular fibromyxoid exudates, interstitial lymphocyte infiltrates, and multinucleated syncytial cells in the intraalveolar spaces ([@bib16]). Consistent with these extensive pathological abnormalities, widespread bilateral ground-glass opacification and/or consolidation on pulmonary computed tomography were present in all decedents with COVID-19 pneumonia, accounting for the fact that dyspnea was a remarkable symptom. Unfortunately, because these patients had very severe disease, none of them had the chance to undergo a second computed tomography scan. These patients experienced symptoms for a median of ∼10 days before they were hospitalized, but rapidly worsened and required care in the ICU within a short time. Some patients with severe disease died right after they arrived at the hospital, and some died in general wards before they were admitted to the ICU at Tianyou Hospital or Central Hospital, or were transferred to Pulmonary Hospital or Wuhan Jinyintan Hospital for critical care. Although 45 patients in Pulmonary Hospital had an opportunity to receive advanced ventilatory support and rescue therapies for profound hypoxemic respiratory failure, including noninvasive ventilation, invasive ventilation, high-frequency oscillatory ventilation, and extracorporeal membrane oxygenation, they did not survive owing to rapidly progressive multiple organ failure, especially respiratory failure and heart failure.

No antiviral drug, antibiotic, antifungal drug, corticosteroid treatment, or immune globulin is routinely recommended for treatment of COVID-19 pneumonia ([@bib7]); however, a combination of two or more of these drugs was given to all patients included in the study. Antiviral drugs were prescribed because a diagnosis of influenza had been suspected or could not be excluded before the SARS-CoV-2 test result was available. Empirical broad-spectrum antibacterial agents and/or antifungal regimens were initiated because of a suspicion of community-acquired bacterial pneumonia and/or secondary bacterial and fungal infection. However, actual lung bacterial or fungal infections were documented in only 42 patients (38.5%) in the late stage of disease. It was believed that corticosteroids might be able to alleviate the inflammatory response in the patients' lungs, and therefore were given to most patients.

As mentioned above, patients who were admitted to an ICU lived longer than those who were not, because the ICU group received more active therapies, including mechanical ventilation, continuous renal-replacement therapy, and extracorporeal membrane oxygenation. Unfortunately, all 51 patients who were admitted to an ICU eventually died there; because of the rapidly progressive nature of this disease, none had a chance to be transferred to a general ward. It is possible that some of these patients could have survived if they had received earlier ICU care, especially earlier incubation and invasive ventilation.

This study has a major strength. It represents the largest and most detailed series of nonsurvivors of severe COVID-19 pneumonia yet described. These observations of typical clinical features, laboratory findings, and responses to therapy should aid in the recognition and clinical management of such infections, especially with regard to ICU resource allocation. This study also has major limitations. One is that we did not provide comparisons of nonsurvivors and survivors in this observational study. Another major limitation is that only decedents from three designated COVID-19 hospitals were included in the present study. Actually, there were 35 such hospitals in the urban districts of Wuhan.

In conclusion, our analysis of a multicenter cohort of decedents with COVID-19 pneumonia reveals that deaths were concentrated in an older patient group, especially those with one or more underlying diseases. Because multiple organ failure, especially respiratory failure and heart failure, occurred rapidly after hospital admission, ICU care should be provided as soon as possible for patients with severe COVID-19 pneumonia. A social distancing policy should be proposed to slow the rate of cases and prevent healthcare systems from being overwhelmed by patients for whom they cannot provide ICU care.
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